UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6694) 6694
Book Chapter (7) 7
Newsletter (3) 3
Book / eBook (2) 2
Web Resource (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
Magazine Article (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4038) 4038
vinblastine - pharmacology (3396) 3396
science & technology (3356) 3356
life sciences & biomedicine (3258) 3258
biological and medical sciences (3061) 3061
animals (2855) 2855
medical sciences (2672) 2672
pharmacology. drug treatments (2388) 2388
female (2284) 2284
male (2222) 2222
antineoplastic agents (2047) 2047
vinblastine - administration & dosage (1823) 1823
oncology (1776) 1776
chemotherapy (1558) 1558
antineoplastic combined chemotherapy protocols - therapeutic use (1547) 1547
middle aged (1520) 1520
vinblastine - analogs & derivatives (1479) 1479
adult (1432) 1432
aged (1244) 1244
mice (1051) 1051
vinblastine (991) 991
colchicine - pharmacology (928) 928
pharmacology & pharmacy (851) 851
rats (823) 823
antineoplastic combined chemotherapy protocols - adverse effects (753) 753
vinblastine - therapeutic use (728) 728
vinblastine - adverse effects (719) 719
cisplatin - administration & dosage (704) 704
vinorelbine (675) 675
antineoplastic agents - pharmacology (579) 579
microtubules - drug effects (571) 571
lung neoplasms - drug therapy (567) 567
treatment outcome (561) 561
dose-response relationship, drug (549) 549
time factors (518) 518
doxorubicin - administration & dosage (515) 515
antineoplastic agents, phytogenic - pharmacology (486) 486
cell line (468) 468
abridged index medicus (451) 451
tumor cells, cultured (435) 435
carcinoma, non-small-cell lung - drug therapy (429) 429
fundamental and applied biological sciences. psychology (428) 428
bleomycin - administration & dosage (426) 426
tumors (422) 422
breast neoplasms - drug therapy (420) 420
general aspects (414) 414
kinetics (409) 409
vinblastine - metabolism (408) 408
cancer (405) 405
drug resistance (397) 397
adolescent (380) 380
biochemistry & molecular biology (379) 379
neoplasm staging (358) 358
cell line, tumor (357) 357
cells, cultured (347) 347
combined modality therapy (346) 346
drug administration schedule (346) 346
vincristine - pharmacology (342) 342
hodgkin disease - drug therapy (332) 332
in vitro techniques (329) 329
vinblastine - pharmacokinetics (326) 326
survival analysis (325) 325
antineoplastic combined chemotherapy protocols - administration & dosage (321) 321
cell biology (318) 318
tubulin - metabolism (316) 316
microscopy, electron (298) 298
doxorubicin - pharmacology (297) 297
paclitaxel - pharmacology (293) 293
survival rate (286) 286
drug resistance, neoplasm (285) 285
cell division - drug effects (281) 281
microtubules - metabolism (270) 270
deoxycytidine - analogs & derivatives (266) 266
p-glycoprotein (266) 266
mitosis - drug effects (258) 258
antineoplastic agents, phytogenic - administration & dosage (255) 255
cell survival - drug effects (255) 255
antineoplastic agents - therapeutic use (253) 253
cytochalasin b - pharmacology (250) 250
research (249) 249
aged, 80 and over (248) 248
disease-free survival (243) 243
microtubules (243) 243
breast neoplasms - pathology (240) 240
methotrexate - administration & dosage (236) 236
lung neoplasms - pathology (235) 235
neoplasm metastasis (231) 231
vincristine - administration & dosage (230) 230
drug resistance, multiple (228) 228
multidrug resistance (222) 222
prognosis (218) 218
cisplatin (216) 216
drug synergism (216) 216
follow-up studies (216) 216
verapamil - pharmacology (214) 214
breast cancer (212) 212
cisplatin - adverse effects (212) 212
dacarbazine - administration & dosage (212) 212
etoposide - administration & dosage (211) 211
medicine & public health (209) 209
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6500) 6500
Japanese (94) 94
Russian (59) 59
French (58) 58
German (42) 42
Italian (24) 24
Chinese (22) 22
Spanish (6) 6
Polish (4) 4
Hungarian (3) 3
Portuguese (3) 3
Dutch (2) 2
Romanian (2) 2
Bulgarian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Pneumology | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology | Index Medicus
Journal Article
Oncogene, ISSN 0950-9232, 04/1999, Volume 18, Issue 13, pp. 2241 - 2251
Chemotherapy | Breast cancer | Synergy | Multiple drug effects analysis | HER-2/neu (c-erbB-2) | Biochemistry & Molecular Biology | Oncology | Genetics & Heredity | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Fundamental and applied biological sciences. Psychology | Biological and medical sciences | Cell physiology | Molecular and cellular biology | Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes | Recombinant Proteins - therapeutic use | Doxorubicin - therapeutic use | Adenocarcinoma - pathology | Receptor, ErbB-2 - genetics | Humans | Neoplasm Proteins - immunology | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Vinblastine - therapeutic use | Topoisomerase II Inhibitors | Antimetabolites, Antineoplastic - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Receptor, ErbB-2 - biosynthesis | Antibodies, Monoclonal - pharmacology | Etoposide - pharmacology | Combined Modality Therapy | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Drug Synergism | Antimetabolites, Antineoplastic - therapeutic use | Adenocarcinoma - therapy | Antibiotics, Antineoplastic - therapeutic use | Mice, Nude | Cyclophosphamide - pharmacology | Immunization, Passive | Fluorouracil - pharmacology | Mice | Cell Cycle - drug effects | Trastuzumab | Neoplasm Transplantation | Paclitaxel - pharmacology | Antibiotics, Antineoplastic - pharmacology | Antineoplastic Agents, Alkylating - pharmacology | Transplantation, Heterologous | Fluorouracil - antagonists & inhibitors | Cyclophosphamide - therapeutic use | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Protein Processing, Post-Translational - drug effects | Female | Antineoplastic Agents - pharmacology | Thiotepa - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - biosynthesis | Etoposide - therapeutic use | Treatment Outcome | Cisplatin - pharmacology | Recombinant Proteins - pharmacology | Paclitaxel - therapeutic use | Neoplasms, Hormone-Dependent - therapy | Animals | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Vinblastine - pharmacology | Neoplasms, Hormone-Dependent - drug therapy | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 5/2011, Volume 67, Issue 5, pp. 1157 - 1166
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2005, Volume 11, Issue 20, pp. 7508 - 7515
BRCA1, BRCA2 | Xenograft models | DNA damage and repair mechanisms | Pharmacogenetics/pharmacogenomics | Gastrointestinal cancers: other | Life Sciences & Biomedicine | Oncology | Science & Technology | Chromosome fragility (bloom syndrome, ataxia telangiectasia, fanconi anemia, x-linked mental retardation...) | Chemotherapy | Pharmacology. Drug treatments | Medical genetics | Biological and medical sciences | Medical sciences | Antineoplastic agents | Paclitaxel - pharmacology | Apoptosis - drug effects | Cross-Linking Reagents - pharmacology | Humans | Deoxycytidine - pharmacology | Chlorambucil - pharmacology | Fanconi Anemia Complementation Group C Protein - genetics | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Caspases - metabolism | Fanconi Anemia Complementation Group G Protein - genetics | Time Factors | Cross-Linking Reagents - therapeutic use | Fanconi Anemia Complementation Group G Protein - deficiency | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Melphalan - pharmacology | Cell Survival - drug effects | Fanconi Anemia Complementation Group Proteins - deficiency | Mitomycin - therapeutic use | Pancreatic Neoplasms - pathology | Fanconi Anemia Complementation Group Proteins - genetics | Etoposide - pharmacology | Pancreatic Neoplasms - genetics | Cisplatin - pharmacology | Xenograft Model Antitumor Assays - methods | Mitomycin - pharmacology | Animals | Mice, Nude | Cell Line, Tumor | Fanconi Anemia Complementation Group C Protein - deficiency | BRCA2 Protein - deficiency | Fluorouracil - pharmacology | Mice | Vinblastine - pharmacology | Mutation | Cell Cycle - drug effects | BRCA2 Protein - genetics | Deoxycytidine - analogs & derivatives | Doxorubicin - pharmacology | Index Medicus
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 03/2008, Volume 75, Issue 6, pp. 1302 - 1312
Journal Article
Nature cell biology, ISSN 1465-7392, 03/2007, Volume 9, Issue 3, pp. 299 - 309
Life Sciences & Biomedicine | Science & Technology | Cell Biology | Nonmuscle Myosin Type IIA - antagonists & inhibitors | Embryonic Stem Cells - metabolism | RNA, Small Interfering - genetics | Embryonic Stem Cells - cytology | Humans | Nocodazole - pharmacology | Cercopithecus aethiops | Cell Movement - physiology | Heterocyclic Compounds, 4 or More Rings - pharmacology | Microtubules - metabolism | Nonmuscle Myosin Type IIB - antagonists & inhibitors | Transfection | Nonmuscle Myosin Type IIA - physiology | Guanine Nucleotide Exchange Factors - metabolism | Microtubules - drug effects | Nonmuscle Myosin Type IIA - genetics | Kinesin - genetics | Aminoquinolines - pharmacology | Kinesin - antagonists & inhibitors | T-Lymphoma Invasion and Metastasis-inducing Protein 1 | Nonmuscle Myosin Type IIB - physiology | Fibroblasts - metabolism | Guanine Nucleotide Exchange Factors - genetics | Nonmuscle Myosin Type IIB - genetics | Enzyme Inhibitors - pharmacology | Pyrimidines - pharmacology | Actomyosin - metabolism | Kinesin - metabolism | Naphthalenes - pharmacology | Azepines - pharmacology | Cell Movement - drug effects | Animals | Embryonic Stem Cells - drug effects | Cell Adhesion - physiology | Fibroblasts - drug effects | rac1 GTP-Binding Protein - antagonists & inhibitors | Fibroblasts - cytology | Mice | Vinblastine - pharmacology | Thiones - pharmacology | COS Cells | rac1 GTP-Binding Protein - metabolism | rac1 GTP-Binding Protein - genetics | Evaluation | Motility | Microtubules | Myosin | Physiological aspects | Genetic aspects | Properties | Health aspects | Cells | Index Medicus
Journal Article
Molecules (Basel, Switzerland), ISSN 1420-3049, 12/2017, Volume 22, Issue 12, p. 2152
FGFR2α | Resistance | Gastrointestinal stromal tumor cells (GISTs) | Imatinib (IM) | Receptor tyrosine kinase (RTK) inhibitors | Chemotherapeutic drugs | Biochemistry & Molecular Biology | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Gastrointestinal Stromal Tumors - enzymology | Proto-Oncogene Proteins c-met - metabolism | Focal Adhesion Kinase 1 - genetics | Paclitaxel - pharmacology | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Epithelial Cells - drug effects | Humans | Gene Expression Regulation, Neoplastic | Proto-Oncogene Proteins c-kit - metabolism | Proto-Oncogene Proteins c-akt - genetics | Gastrointestinal Stromal Tumors - pathology | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Focal Adhesion Kinase 1 - metabolism | Gastrointestinal Stromal Tumors - genetics | Pyrazoles - pharmacology | Receptor, Platelet-Derived Growth Factor alpha - metabolism | Signal Transduction | Imatinib Mesylate - pharmacology | Epithelial Cells - pathology | Pyrimidines - pharmacology | Proto-Oncogene Proteins c-met - genetics | Drug Resistance, Neoplasm - genetics | Receptor, Platelet-Derived Growth Factor alpha - genetics | Anilides - pharmacology | Epithelial Cells - enzymology | Cell Line, Tumor | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Vinblastine - pharmacology | Doxorubicin - pharmacology | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Drug Resistance, Neoplasm - drug effects | Fibroblast growth factor | Target recognition | DNA damage | Chemoresistance | Drug resistance | DNA repair | Metastases | Axl protein | c-Met protein | Proteins | Clonal deletion | Protein-tyrosine kinase receptors | Inhibition | Repair | Protein-tyrosine kinase | Growth kinetics | Deoxyribonucleic acid--DNA | Tyrosine | Imatinib | Double-strand break repair | Insulin | c-Kit protein | Amplification | Signaling | Chemotherapy | Reagents | In vivo methods and tests | Mutation | Kinetics | Focal adhesion kinase | Transporter | Tumors | Apoptosis | Fibroblast growth factor receptors | Index Medicus | gastrointestinal stromal tumor cells (GISTs) | imatinib (IM) | receptor tyrosine kinase (RTK) inhibitors | chemotherapeutic drugs | resistance
Journal Article
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 2/2007, Volume 59, Issue 2, pp. 157 - 164